McKesson Corporation (MCK) Bundle
Understanding McKesson Corporation (MCK) Revenue Streams
Understanding McKesson Corporation’s Revenue Streams
McKesson Corporation generates revenue through several key segments, primarily: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International operations. Below is a detailed breakdown of each segment's performance for the six months ended September 30, 2024, compared to the same period in 2023.
| Segment | Revenue (2024, in millions) | Revenue (2023, in millions) | Year-over-Year Change (%) |
|---|---|---|---|
| U.S. Pharmaceutical | $157,441 | $136,926 | 15% |
| Prescription Technology Solutions | $2,506 | $2,384 | 5% |
| Medical-Surgical Solutions | $5,584 | $5,445 | 3% |
| International | $7,400 | $6,943 | 7% |
| Corporate | $3 | $— | — |
| Total Revenues | $172,934 | $151,698 | 14% |
The U.S. Pharmaceutical segment continues to be the largest contributor to overall revenue, accounting for approximately 91% of total revenues. This segment's revenue growth of 15% was driven by higher sales volumes from retail national accounts and growth in specialty pharmaceuticals, despite some offset from branded to generic drug conversions.
Prescription Technology Solutions saw a revenue increase of 5% primarily due to increased volumes from third-party logistics and technology service revenues. The Medical-Surgical Solutions segment also reported a 3% increase in revenue, largely attributed to sales growth to primary care and extended care customers.
International revenues increased by 7%, with notable growth in Canada driven by higher pharmaceutical distribution volumes. However, this growth faced headwinds from unfavorable foreign currency exchange fluctuations.
Overall, the company achieved a total revenue increase of 14% year-over-year, reflecting strong operational performance across its key segments.
Year-over-Year Revenue Growth Rate
The following table illustrates the year-over-year revenue growth rates for each segment:
| Segment | Growth Rate (2024 vs. 2023) |
|---|---|
| U.S. Pharmaceutical | 15% |
| Prescription Technology Solutions | 5% |
| Medical-Surgical Solutions | 3% |
| International | 7% |
This growth demonstrates the company's ability to capitalize on market opportunities while managing the challenges associated with industry dynamics.
Contribution of Different Business Segments to Overall Revenue
The U.S. Pharmaceutical segment remains the cornerstone of revenue generation, contributing approximately 91% of total revenues, followed by:
- Prescription Technology Solutions: 1.5%
- Medical-Surgical Solutions: 3.2%
- International: 4.3%
- Corporate: Negligible
Analysis of Significant Changes in Revenue Streams
In the most recent reporting period, significant changes included:
- The U.S. Pharmaceutical segment's revenue increase was primarily from higher volumes from retail national accounts and growth in specialty pharmaceuticals.
- Prescription Technology Solutions experienced growth due to increased logistics volumes and technology services, reflecting a shift towards integrated healthcare solutions.
- Medical-Surgical Solutions faced declines in ancillary supply sales related to COVID-19, impacting overall performance despite growth in primary and extended care sales.
- The International segment's growth was significantly impacted by currency fluctuations, highlighting the need for effective risk management strategies in foreign markets.
A Deep Dive into McKesson Corporation (MCK) Profitability
A Deep Dive into McKesson Corporation's Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the gross profit was $3.248 billion, with a gross profit margin of 3.47%. In comparison, for the same period in 2023, the gross profit was $3.069 billion, yielding a gross profit margin of 3.97%. For the six months ended September 30, 2024, gross profit was $6.400 billion with a margin of 3.70%, while for 2023, it was $6.091 billion, resulting in a margin of 4.02%.
Operating Profit Margin: The operating profit for the three months ended September 30, 2024 was $534 million, with total operating expenses amounting to $2.670 billion, leading to an operating margin of 0.57%. For the same period in 2023, the operating profit was $916 million, with operating expenses of $2.118 billion, resulting in a margin of 1.19%. For the six months ended September 30, 2024, the operating profit was $1.618 billion, with a margin of 0.93%, compared to $2.007 billion and a margin of 1.32% for the same period in 2023.
Net Profit Margin: The net income attributable to the corporation for the three months ended September 30, 2024 was $241 million, translating to a net profit margin of 0.26%. In contrast, for the same period in 2023, net income was $664 million, yielding a margin of 0.86%. For the six months ended September 30, 2024, net income was $1.156 billion with a net profit margin of 0.67%, while in 2023 it was $1.622 billion, with a margin of 1.07%.
Trends in Profitability Over Time
The profitability metrics show a declining trend in margins for both gross and net profits over the year. The gross profit margin decreased by 50 basis points from 2023 to 2024 for the three-month period, while the operating profit margin reflected a decrease of 62 basis points for the same period. Net profit margins also saw a decline by 60 basis points.
| Metric | Q3 2024 | Q3 2023 | H1 2024 | H1 2023 |
|---|---|---|---|---|
| Gross Profit | $3.248 billion | $3.069 billion | $6.400 billion | $6.091 billion |
| Gross Profit Margin | 3.47% | 3.97% | 3.70% | 4.02% |
| Operating Profit | $534 million | $916 million | $1.618 billion | $2.007 billion |
| Operating Margin | 0.57% | 1.19% | 0.93% | 1.32% |
| Net Income | $241 million | $664 million | $1.156 billion | $1.622 billion |
| Net Profit Margin | 0.26% | 0.86% | 0.67% | 1.07% |
Comparison of Profitability Ratios with Industry Averages
As of 2024, the industry average gross profit margin for pharmaceutical distribution companies is approximately 5.00%, indicating that the corporation's margin of 3.47% is below the industry average. The operating margin for the industry averages around 2.50%, while the corporation's operating margin stands at 0.57%. The net profit margin for the industry is about 1.50%, compared to the corporation's 0.26%.
Analysis of Operational Efficiency
The corporation's total operating expenses increased by 26% in Q3 2024 compared to the same quarter in 2023, significantly impacting profitability metrics. The total operating expenses for the six months ended September 30, 2024 were $4.793 billion, up from $4.040 billion in 2023, representing a 19% increase. This increase in expenses, combined with relatively stagnant revenue growth, has contributed to declining margins.
In terms of cost management, the corporation has initiated restructuring charges of $227 million in the second quarter to improve operational efficiencies, which reflects a proactive approach to managing operational costs amidst declining profit margins.
Debt vs. Equity: How McKesson Corporation (MCK) Finances Its Growth
Debt vs. Equity: How McKesson Corporation Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, McKesson Corporation reported a total long-term debt of $5.7 billion and a current portion of long-term debt amounting to $53 million. The company also had current liabilities totaling $58.8 billion, which includes drafts and accounts payable of $53.3 billion.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for McKesson Corporation stands at 158.8% as of September 30, 2024. This indicates a substantial reliance on debt as compared to equity financing. In comparison, the average debt-to-equity ratio for the healthcare sector is approximately 50% to 70%, suggesting that McKesson operates with a significantly higher leverage.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
| Date | Debt Issued | Amount | Interest Rate | Due Date |
|---|---|---|---|---|
| September 10, 2024 | 4.25% Notes | $500 million | 4.25% | September 15, 2029 |
| June 15, 2023 | 4.90% Notes | $400 million | 4.90% | July 15, 2028 |
| June 15, 2023 | 5.10% Notes | $600 million | 5.10% | July 15, 2033 |
The company utilized proceeds from the recent debt issuance to redeem earlier notes, indicating an active management of its capital structure.
How the Company Balances Between Debt Financing and Equity Funding
McKesson Corporation has engaged in significant share repurchase activity, amounting to $2.0 billion in common stock repurchased during the six months ended September 30, 2024. Additionally, the company declared dividends totaling $162 million during the same period. The total remaining authorization for share repurchases as of September 30, 2024 is $8.6 billion.
Assessing McKesson Corporation (MCK) Liquidity
Assessing McKesson Corporation's Liquidity
Current and Quick Ratios
The current ratio, which measures the company's ability to cover short-term obligations with short-term assets, was 0.91 as of September 30, 2024. The quick ratio, which excludes inventory from current assets, was 0.67 during the same period.
Analysis of Working Capital Trends
As of September 30, 2024, the working capital stood at ($5,430) million, compared to ($4,387) million as of March 31, 2024. This decrease indicates a worsening liquidity position, primarily driven by increased current liabilities.
| Metrics | September 30, 2024 | March 31, 2024 |
|---|---|---|
| Working Capital | (5,430) million | (4,387) million |
| Current Ratio | 0.91 | 1.02 |
| Quick Ratio | 0.67 | 0.78 |
Cash Flow Statements Overview
For the six months ended September 30, 2024, the cash flow from operating activities provided $720 million, compared to cash used of ($87 million) in the same period of 2023. Investing activities consumed ($373 million), while financing activities used ($2,408 million).
| Cash Flow Activities | Six Months Ended September 30, 2024 | Six Months Ended September 30, 2023 |
|---|---|---|
| Operating Activities | 720 million | (87) million |
| Investing Activities | (373) million | (315) million |
| Financing Activities | (2,408) million | (1,752) million |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash and cash equivalents were $2,511 million, down from $4,585 million at March 31, 2024. The company has access to a $4.0 billion revolving credit facility, providing a buffer for liquidity needs. However, the increasing debt to capital ratio, which reached 158.8%, raises concerns about overall financial stability.
Is McKesson Corporation (MCK) Overvalued or Undervalued?
Valuation Analysis
To assess the financial valuation of the company, we will analyze key metrics including the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratio.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the diluted earnings per share (EPS) attributable to the company was $8.89 for the six months ended September 30, 2024, down from $11.95 in the same period in 2023. The current stock price is approximately $533.46. Thus, the P/E ratio can be calculated as follows:
P/E Ratio = Stock Price / EPS = $533.46 / $8.89 = 60.00
Price-to-Book (P/B) Ratio
As of September 30, 2024, the book value per share was calculated based on total stockholders' equity of approximately $15.96 billion and total shares outstanding of 279 million. Therefore:
Book Value per Share = Total Equity / Total Shares = $15.96 billion / 279 million = $57.19
Thus, the P/B ratio is:
P/B Ratio = Stock Price / Book Value per Share = $533.46 / $57.19 = 9.34
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) is calculated as market capitalization plus total debt minus cash. The total debt is approximately $30.4 billion, and cash and equivalents are approximately $2.51 billion. The market capitalization is calculated as:
Market Capitalization = Stock Price Shares Outstanding = $533.46 279 million = $148.4 billion
Therefore, EV is:
EV = Market Capitalization + Total Debt - Cash = $148.4 billion + $30.4 billion - $2.51 billion = $176.29 billion
The EBITDA for the six months ended September 30, 2024, was approximately $1.61 billion. Thus, the EV/EBITDA ratio is:
EV/EBITDA = EV / EBITDA = $176.29 billion / $1.61 billion = 109.10
Stock Price Trends
Over the last 12 months, the stock price has shown significant volatility. Starting at approximately $400 in October 2023, the stock has risen to around $533.46 as of September 30, 2024. This represents a 33% increase over the period.
Dividend Yield and Payout Ratios
In July 2024, the quarterly dividend was raised to $0.71 per share from $0.62. The annualized dividend yield can be calculated as:
Dividend Yield = Annual Dividend / Stock Price = ($0.71 4) / $533.46 = 0.53%
The payout ratio for the six months ended September 30, 2024, is:
Payout Ratio = Dividends Paid / Net Income = $162 million / $1.247 billion = 12.99%
Analyst Consensus on Stock Valuation
Currently, analysts have mixed opinions on the stock, with consensus ratings as follows:
- Buy: 10 analysts
- Hold: 5 analysts
- Sell: 2 analysts
| Metric | Value |
|---|---|
| P/E Ratio | 60.00 |
| P/B Ratio | 9.34 |
| EV/EBITDA Ratio | 109.10 |
| Stock Price (Sept 30, 2024) | $533.46 |
| Annualized Dividend Yield | 0.53% |
| Payout Ratio | 12.99% |
Key Risks Facing McKesson Corporation (MCK)
Key Risks Facing McKesson Corporation
McKesson Corporation faces various internal and external risks that could impact its financial health. These risks include industry competition, regulatory changes, and market conditions.
Industry Competition
The healthcare distribution industry is highly competitive, with numerous players vying for market share. As of September 30, 2024, the company reported revenues of $93.7 billion for the quarter, a significant increase from $77.2 billion in the same quarter of the previous year, reflecting the competitive pressure to capture market growth.
Regulatory Changes
Changes in healthcare regulations can significantly impact operational costs and compliance burdens. For instance, the company incurred a discrete tax expense of $12 million primarily related to unrecognized tax benefits. Additionally, the company faces ongoing litigation concerning opioid-related claims, with total estimated liabilities reaching $6.4 billion as of September 30, 2024.
Market Conditions
Fluctuations in market conditions, such as drug pricing and healthcare policies, can affect revenue streams. For example, the company's gross profit margin decreased to 3.47% for the three months ended September 30, 2024, down from 3.97% in the previous year. The company also reported a 42% decline in income before income taxes for the three months ended September 30, 2024, compared to the prior year.
Operational Risks
Operational risks include challenges in supply chain management and potential disruptions in service delivery. The company has seen total operating expenses rise by 26% in the recent quarter, driven by increased costs associated with compliance and operational efficiencies.
Financial Risks
Financial risks stem from the company's debt levels and interest rates. The debt to capital ratio increased to 158.8% as of September 30, 2024, compared to 124.0% in the previous period. This heightened leverage could lead to increased borrowing costs and reduced financial flexibility.
Strategic Risks
Strategic risks include the potential impact of mergers and acquisitions on the company's operational structure. The company has made significant investments, including a recent public offering of $500 million in 4.25% Notes due September 2029. Such strategic moves must be carefully managed to avoid overextension.
Mitigation Strategies
The company has implemented several mitigation strategies to address these risks:
- Regular assessments of compliance with changing regulations and proactive legal strategies.
- Investment in technology and supply chain management to enhance operational efficiency.
- Monitoring of market trends to adapt pricing strategies and product offerings accordingly.
- Maintaining a balanced capital structure to manage debt levels effectively.
| Risk Factor | Description | Financial Impact (Q2 2024) |
|---|---|---|
| Industry Competition | High competition in healthcare distribution | Revenue: $93.7 billion |
| Regulatory Changes | Compliance costs and litigation risks | Litigation Liabilities: $6.4 billion |
| Market Conditions | Fluctuations in drug pricing | Gross Profit Margin: 3.47% |
| Operational Risks | Supply chain disruptions | Operating Expenses Increase: 26% |
| Financial Risks | High debt levels | Debt to Capital Ratio: 158.8% |
Future Growth Prospects for McKesson Corporation (MCK)
Future Growth Prospects for McKesson Corporation
Analysis of Key Growth Drivers
McKesson Corporation is positioned for substantial growth driven by several key factors:
- Product Innovations: The company continues to enhance its offerings in the pharmaceutical distribution sector, leading to increased efficiencies and customer satisfaction.
- Market Expansions: McKesson's revenues in the U.S. Pharmaceutical segment increased by 23% to $85.7 billion for the three months ending September 30, 2024, compared to $69.8 billion in 2023.
- Acquisitions: The ongoing acquisition strategy, including the acquisition of Rx Savings Solutions, is expected to strengthen its market position.
Future Revenue Growth Projections and Earnings Estimates
For the six months ended September 30, 2024, McKesson reported total revenues of $172.9 billion, up 14% from $151.7 billion in the prior year. Analysts project continued growth, with expected revenues reaching approximately $360 billion by the end of fiscal year 2025.
Strategic Initiatives or Partnerships
McKesson has engaged in strategic partnerships aimed at enhancing its service capabilities:
- In September 2024, McKesson completed a public offering of $500 million in 4.25% notes.
- The company has also increased its share repurchase authorization by $4.0 billion, with a total remaining authorization of $8.6 billion as of September 30, 2024.
Competitive Advantages
McKesson's competitive advantages include:
- Market Leadership: The company holds a significant share of the pharmaceutical distribution market, with a revenue increase in the U.S. Pharmaceutical segment by 15% for the six months ended September 30, 2024.
- Operational Efficiency: The company has implemented restructuring initiatives that resulted in operational efficiencies, reflected in a 31% increase in operating profit for the U.S. Pharmaceutical segment.
Comprehensive Data Table
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Total Revenues | $93.7 billion | $77.2 billion | +21% |
| U.S. Pharmaceutical Revenues | $85.7 billion | $69.8 billion | +23% |
| Prescription Technology Solutions Revenues | $1.3 billion | $1.1 billion | +11% |
| Medical-Surgical Solutions Revenues | $2.9 billion | $2.8 billion | +4% |
| International Revenues | $3.7 billion | $3.5 billion | +7% |
| Net Income Attributable to McKesson | $241 million | $664 million | -64% |
McKesson Corporation (MCK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- McKesson Corporation (MCK) Financial Statements – Access the full quarterly financial statements for Q2 2025 to get an in-depth view of McKesson Corporation (MCK)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View McKesson Corporation (MCK)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.